<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Fitzpatrick | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/rattaurus3/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/rattaurus3/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Fitzpatrick.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">fbb876da2e9bbb5d45a35d7ebeb018b5</guid>
				<title>Fitzpatrick posted an update: Taken together, the findings of the present study [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41489/</link>
				<pubDate>Sat, 08 Feb 2025 09:10:20 -0800</pubDate>

									<content:encoded><![CDATA[<p>Taken together, the findings of the present study demonstrate that RP11‑340F14.6 specifically binds to P2X7R, which results in the continuous activation of P2X7R. Thus, RP11‑340F14.6 may serve as a promising therapeutic target for the treatment of JIA.Supplemental oxygen therapy can be life‑saving for premature infants. Our previous study revea&hellip;<span class="activity-read-more" id="activity-read-more-41489"><a href="http://www.nationalboardinstitute.com/activity/p/41489/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e5854b27d52e9be5e51a9d38dfdc530f</guid>
				<title>Fitzpatrick posted an update: In conclusion, PEB was a safe and effective tool to treat [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/37024/</link>
				<pubDate>Mon, 03 Feb 2025 08:44:57 -0800</pubDate>

									<content:encoded><![CDATA[<p>In conclusion, PEB was a safe and effective tool to treat in-stent restenosis and de novo coronary lesions, especially small vessel disease, during long-term follow-up.It has long been recognized that liquid interfaces, such as the air-water interface (AWI), can enhance the formation of protein fibrils. This makes liquid interfaces attractive&hellip;<span class="activity-read-more" id="activity-read-more-37024"><a href="http://www.nationalboardinstitute.com/activity/p/37024/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">23b911336ed22228720386ec0c711031</guid>
				<title>Fitzpatrick posted an update: The Bostwick autoderm technique uses the patient's own [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35202/</link>
				<pubDate>Sat, 01 Feb 2025 08:39:20 -0800</pubDate>

									<content:encoded><![CDATA[<p>The Bostwick autoderm technique uses the patient&#8217;s own deepithelialized mastectomy flap for lower pole coverage of an implant, similar to the use of acellular dermal matrix. The skin is closed over the autoderm flap in a Wise pattern. Unlike acellular dermal matrix, autoderm is perfused tissue that offers immediate protection for the implant.&hellip;<span class="activity-read-more" id="activity-read-more-35202"><a href="http://www.nationalboardinstitute.com/activity/p/35202/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">e2fb94e7c0bf9eab0a538ebc216b173e</guid>
				<title>Fitzpatrick posted an update: The association between the pathological response rate and [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/33426/</link>
				<pubDate>Thu, 30 Jan 2025 09:14:48 -0800</pubDate>

									<content:encoded><![CDATA[<p>The association between the pathological response rate and survival will be evaluated in the final analysis of this clinical trial.</p>
<p>Preoperative docetaxel, cisplatin and S-1 therapy was feasible in terms of chemotherapy-related toxicities and surgical morbidity, but the effect did not achieve the expected value. The association between the&hellip;<span class="activity-read-more" id="activity-read-more-33426"><a href="http://www.nationalboardinstitute.com/activity/p/33426/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">ba3ecebd5def009481a1bd811bc0dc46</guid>
				<title>Fitzpatrick posted an update: Pyrazole and its derivatives have gained wide attention in [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/27090/</link>
				<pubDate>Tue, 28 Jan 2025 08:45:56 -0800</pubDate>

									<content:encoded><![CDATA[<p>Pyrazole and its derivatives have gained wide attention in pharmaceutical, agrochemical and biological fields as well as in industry. They exhibit various biological activities such as anti-pyretic, anti-microbial, anti- inflammatory, anti-tumor, anti-viral, anti-histaminic, anti-convulsant, fungicidal, insecticidal, etc. In this review, we&hellip;<span class="activity-read-more" id="activity-read-more-27090"><a href="http://www.nationalboardinstitute.com/activity/p/27090/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3d535ef005f898a702e96b936dbe8590</guid>
				<title>Fitzpatrick became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/27042/</link>
				<pubDate>Tue, 28 Jan 2025 08:43:07 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>